Stock listing
Dusseldorf:4AJ0 ALK-abello A/S Aktie
German listing (Dusseldorf) of ALK-abello A/S · home listing Copenhagen:ALKB
Follow ALK-abello A/S into a list and get an email when it puts out news.
Home listing price · OMXCOP:ALK_B
239.20 DKK -3.80 (-1.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXCOP:ALK_B
- Day range
- 238.60 – 244.00 DKKNov 20, 2026
- Volume
- 201,585 sharesNov 20, 2026
- Market cap
- 48.16B DKKAt the close on Nov 20, 2026 · price × 201.3M shares outstanding
- 52-week range
- 191.80 – 271.40 DKKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 52.26M DKKMedian day 205,784 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:AKBLF | $36.50 USD | 0.00 (0.0%) | — | $36.50 | $36.50 | $36.50 | $36.50 | Close on Nov 6, 2026 |
| Frankfurt:4AJ0 | €32.34 EUR | -0.10 (-0.3%) | — | €32.34 | €32.34 | €32.34 | €32.44 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXCOP:ALK_B · DKK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 239.20 | -3.80 | -1.6% | 243.80 | 244.00 | 238.60 | 201,585 | |
| 243.00 | -3.00 | -1.2% | 246.60 | 248.00 | 239.40 | 357,193 | |
| 246.00 | -7.20 | -2.8% | 250.00 | 251.80 | 229.00 | 422,497 | |
| 253.20 | +4.80 | +1.9% | 248.40 | 253.60 | 248.00 | 252,835 | |
| 248.40 | -0.40 | -0.2% | 249.00 | 250.00 | 247.60 | 100,659 | |
| 248.80 | +1.00 | +0.4% | 248.60 | 250.80 | 246.80 | 181,689 | |
| 247.80 | +2.20 | +0.9% | 246.60 | 248.40 | 245.20 | 128,195 | |
| 245.60 | +2.80 | +1.2% | 244.60 | 245.80 | 241.80 | 211,293 | |
| 242.80 | -3.60 | -1.5% | 243.60 | 244.40 | 240.00 | 121,558 | |
| 246.40 | +2.80 | +1.1% | 244.40 | 248.00 | 244.40 | 155,238 | |
| 243.60 | -3.20 | -1.3% | 246.60 | 248.00 | 243.60 | 177,049 | |
| 246.80 | +1.60 | +0.7% | 244.80 | 247.20 | 242.20 | 150,403 | |
| 245.20 | -2.80 | -1.1% | 246.00 | 248.20 | 245.20 | 116,653 | |
| 248.00 | +1.40 | +0.6% | 250.00 | 252.00 | 246.40 | 137,802 | |
| 246.60 | +3.00 | +1.2% | 244.00 | 247.40 | 241.40 | 294,653 | |
| 243.60 | +0.20 | +0.1% | 242.60 | 244.40 | 240.60 | 147,088 | |
| 243.40 | +1.60 | +0.7% | 241.80 | 243.60 | 240.60 | 162,118 | |
| 241.80 | -1.00 | -0.4% | 243.20 | 245.60 | 241.20 | 149,725 | |
| 242.80 | +2.20 | +0.9% | 241.20 | 243.40 | 237.40 | 156,341 | |
| 240.60 | -2.00 | -0.8% | 243.00 | 243.20 | 239.40 | 126,480 | |
| 242.60 | +4.80 | +2.0% | 239.00 | 243.80 | 239.00 | 257,796 | |
| 237.80 | +0.80 | +0.3% | 238.80 | 239.20 | 236.80 | 232,917 | |
| 237.00 | +9.60 | +4.2% | 228.80 | 238.20 | 227.60 | 400,301 | |
| 227.40 | -5.40 | -2.3% | 231.60 | 232.40 | 226.60 | 148,850 | |
| 232.80 | +6.80 | +3.0% | 226.00 | 232.80 | 226.00 | 253,054 | |
| 226.00 | -1.20 | -0.5% | 226.60 | 228.20 | 224.40 | 219,799 | |
| 227.20 | -0.80 | -0.4% | 228.00 | 231.80 | 225.40 | 223,185 | |
| 228.00 | +0.60 | +0.3% | 227.00 | 231.00 | 225.00 | 281,950 | |
| 227.40 | -0.80 | -0.4% | 228.20 | 229.80 | 224.80 | 251,746 | |
| 228.20 | +10.20 | +4.7% | 232.80 | 235.80 | 228.00 | 575,593 | |
| 218.00 | +11.00 | +5.3% | 213.20 | 219.20 | 211.00 | 351,244 | |
| 207.00 | +4.60 | +2.3% | 205.00 | 211.00 | 205.00 | 349,035 | |
| 202.40 | +0.80 | +0.4% | 201.60 | 206.80 | 201.60 | 195,116 | |
| 201.60 | +4.10 | +2.1% | 197.40 | 204.00 | 196.30 | 219,254 | |
| 197.50 | -0.90 | -0.5% | 197.50 | 199.30 | 194.10 | 246,820 | |
| 198.40 | +2.10 | +1.1% | 196.10 | 200.20 | 196.00 | 201,186 | |
| 196.30 | -4.70 | -2.3% | 201.00 | 201.20 | 196.30 | 236,162 | |
| 201.00 | +1.30 | +0.7% | 199.30 | 201.00 | 197.80 | 185,243 | |
| 199.70 | +2.90 | +1.5% | 196.50 | 199.70 | 195.60 | 198,183 | |
| 196.80 | -1.20 | -0.6% | 196.90 | 199.20 | 196.70 | 150,535 | |
| 198.00 | -3.00 | -1.5% | 200.00 | 204.00 | 198.00 | 251,653 | |
| 201.00 | +1.90 | +1.0% | 199.10 | 201.60 | 198.50 | 145,994 | |
| 199.10 | +0.60 | +0.3% | 198.50 | 199.60 | 196.20 | 183,936 | |
| 198.50 | -0.50 | -0.3% | 200.00 | 200.00 | 197.10 | 303,815 | |
| 199.00 | +4.90 | +2.5% | 193.70 | 199.00 | 192.50 | 224,542 | |
| 194.10 | +1.80 | +0.9% | 192.90 | 195.00 | 192.30 | 164,214 | |
| 192.30 | -2.90 | -1.5% | 195.00 | 195.20 | 191.80 | 235,025 | |
| 195.20 | -0.70 | -0.4% | 196.80 | 198.00 | 194.60 | 180,801 | |
| 195.90 | -3.30 | -1.7% | 199.20 | 199.40 | 195.90 | 184,693 | |
| 199.20 | -0.80 | -0.4% | 199.40 | 202.80 | 198.60 | 228,842 | |
| 200.00 | -4.60 | -2.2% | 204.40 | 204.60 | 198.20 | 265,195 | |
| 204.60 | -1.40 | -0.7% | 206.60 | 207.20 | 204.20 | 81,652 | |
| 206.00 | -2.80 | -1.3% | 207.60 | 208.00 | 205.80 | 97,716 | |
| 208.80 | -0.40 | -0.2% | 209.20 | 210.40 | 208.60 | 140,207 | |
| 209.20 | -0.80 | -0.4% | 210.00 | 213.60 | 209.20 | 156,538 | |
| 210.00 | -0.80 | -0.4% | 210.80 | 213.00 | 209.00 | 311,929 | |
| 210.80 | +2.00 | +1.0% | 208.00 | 210.80 | 205.20 | 285,857 | |
| 208.80 | +0.20 | +0.1% | 208.00 | 211.00 | 208.00 | 383,782 | |
| 208.60 | -3.60 | -1.7% | 212.20 | 213.60 | 208.00 | 200,709 | |
| 212.20 | +2.00 | +1.0% | 210.00 | 214.00 | 208.60 | 205,784 | |
| 210.20 | +1.40 | +0.7% | 208.20 | 211.80 | 206.60 | 431,895 | |
| 208.80 | -5.40 | -2.5% | 214.20 | 216.20 | 208.80 | 682,389 | |
| 214.20 | -1.80 | -0.8% | 216.80 | 217.80 | 212.00 | 173,619 | |
| 216.00 | +7.00 | +3.3% | 212.80 | 216.00 | 207.60 | 368,324 | |
| 209.00 | -14.60 | -6.5% | 227.00 | 228.40 | 208.40 | 648,552 |
Splits
4 splits since 1992 · OMXCOP:ALK_B · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 20-for-1 | Split | |
| 2-for-1 | Split | |
| 5-for-1 | Split | |
| 39-for-37 | Split |
- Ticker
- Dusseldorf:4AJ0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · May 4, 2026
ALK upgrades its full-year outlook
Latest earnings call · Aug 20, 2026
ALK-abello (Copenhagen:ALK B) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 20, 2026
Q2 2026 Earnings Presentation
Earnings · 10 slides
Latest news
ALK upgrades its full-year outlook
May 4, 2026
Closed 259.00 (+7.0%) on May 4, 2026
Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
Apr 28, 2026
Closed 234.80 (+0.3%) on Apr 29, 2026
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
Mar 16, 2026
Closed 213.00 (+0.4%) on Mar 17, 2026
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
Mar 4, 2026
Closed 223.00 (+3.7%) on Mar 4, 2026
Annual General Meeting in ALK-Abelló A/S on 16 March 2026
Feb 20, 2026
Closed 214.60 (-2.5%) on Feb 20, 2026
Henriette Mersebach to step down as ALK’s head of R&D
Feb 20, 2026
Closed 214.60 (-2.5%) on Feb 20, 2026
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
Feb 13, 2026
Closed 212.00 (-1.1%) on Feb 13, 2026
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
Feb 2, 2026
Closed 212.00 (+2.1%) on Feb 2, 2026
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Jan 29, 2026
Closed 207.60 (-1.3%) on Jan 30, 2026
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
Jan 8, 2026
Closed 230.00 (+0.8%) on Jan 9, 2026
ALK-abello A/S on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 13 in the last 12 months · 27 in all · newest May 4, 2026 · oldest 2025
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
- Decks
- 14 decks · latest Aug 20, 2026
Where ALK-abello A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:ALKB · Home listing | Copenhagen | Denmark | DKK |
| OTC:AKBLF | OTC | United States | USD |
| Tradegate:4AJ0 | Tradegate | Germany | EUR |
| gettex:4AJ0 | gettex | Germany | EUR |
| VIE:ALKB | Vienna | Austria | EUR |
| Aquis:ALKBC | Aquis | United Kingdom | DKK |
| Stuttgart:4AJ0 | Stuttgart | Germany | EUR |
| LS Exchange:A3DHX9 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DHX9 | Lang & Schwarz | Germany | EUR |
| LSIN:0OIR | LSIN | United Kingdom | DKK |
| Frankfurt:4AJ0 | Frankfurt | Germany | EUR |
| Turquoise:ALKBC | Turquoise | United Kingdom | DKK |
| Aquis:ALKBC | Aquis | United Kingdom | DKK |
| Munich:4AJ0 | Munich | Germany | EUR |
| Dusseldorf:4AJ0 · This page | Dusseldorf | Germany | EUR |
| Hamburg:4AJ0 | Hamburg | Germany | EUR |
| Hanover:4AJ0 | Hanover | Germany | EUR |
| Xetra:4AJ0 | Xetra | Germany | EUR |
Valuation
P/E 34.3× against a median of 18.7×: 7th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 46.49B DKK
- P/E
- 34.3×
- EV/sales
- 6.6×
- EV/EBITDA
- 20.9×
- Price/book
- 6.6×
- Gross margin
- 68.0%
- Operating margin
- 26.5%
- Net margin
- 19.9%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ALK-abello A/S Class B · OMXCOP:ALK_B | US$7.07B | US$6.82B | 34.3× | 6.6× | 20.9× | 6.6× | 19.9% | 0.1× | n/a |
| Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM | US$7.79B | US$7.57B | n/a | 27.0× | n/a | 88.6× | −69.0% | 1.2× | 1.20 |
| Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX | US$7.36B | US$10.14B | 55.2× | 3.2× | 16.0× | 13.8× | 4.2% | 5.5× | 0.67 |
| Chemical Works of Gedeon Richter PLC · BET:RICHTER | US$7.13B | US$6.29B | 10.4× | 2.3× | 5.6× | 1.8× | 25.0% | 0.0× | n/a |
| Corcept Therapeutics Incorporated · NASDAQ:CORT | US$6.88B | US$6.52B | 42.4× | 6.8× | 57.2× | 8.3× | 16.8% | 0.0× | 1.59 |
| Alkem Laboratories Ltd. · NSE:ALKEM | US$6.69B | US$6.78B | 30.0× | 4.0× | 20.0× | 4.2× | 13.2% | 0.2× | n/a |
| Huadong Medicine Co., Ltd. Class A · SZSE:000963 | US$6.53B | US$5.95B | 12.7× | 0.9× | n/a | 1.7× | 7.8% | 0.0× | n/a |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A · SZSE:000999 | US$6.48B | US$5.85B | 13.4× | 1.3× | n/a | 1.9× | 10.4% | 0.1× | n/a |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A · SSE:600196 | US$6.44B | US$6.39B | 12.2× | 1.0× | n/a | 0.8× | 8.2% | 0.3× | n/a |
| Mirum Pharmaceuticals, Inc. · NASDAQ:MIRM | US$6.28B | US$6.65B | n/a | 9.9× | n/a | n/a | −134.8% | n/a | 0.83 |
| Apotex Health Corp. · TSX:APTX | US$6.23B | US$7.67B | 23.9× | 3.1× | 11.8× | 25.5× | 10.7% | 6.7× | n/a |
| Median of the others | US$6.61B | US$6.58B | 18.7× | 3.2× | 16.0× | 4.2× | 9.3% | 0.2× | 1.01 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 289.67 DKK · Analysts' mean
- EPS, year to Dec 2026
- 6.89 · 6 analysts
- Revenue, year to Dec 2026
- 7.36B · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Peter Halling | President & CEO |
| Claus Steensen Sølje | Executive Vice President & CFO |
| Christian G. Houghton | Executive Vice President, Product Supply |
| Edward Jordan | Executive Vice President, Commercial Operations North America |
| Flora Beiche-Scholz | Executive Vice President, Commercial Operations Europe |
| Jacob Glenting | EVP Global Research & Development |
| Jan Engel | Senior Vice President, Global Quality |
| Lika Thiesen | Executive Vice President, Global People & Organisation |
| Tina Abild Olesen | EVP Corporate, Portfolio and Product Strategy |
Board
| Director | Role |
|---|---|
| Anders Hedegaard | Chair of the Board |
| Alan Main | Board member |
| Bertil Lindmark | Board member |
| Gitte Aabo | Board member |
| Jesper Høiland | Independent Director |
| Johan Smedsrud | Board member |
| Katja Barnkob | Board Member |
| Lars Holmqvist | Board member |
| Lene Skole | Vice Chair |
| Lise Lund Mærkedahl | Board member |
| Nanna Carlson | Board Member |
Events
- Next results
- Feb 9, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| ALK-abello (Copenhagen:ALK B) Q2 2026 Earnings Call | Thu, Aug 20, 2026 · 7:30 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q1 2026 Earnings Call | Mon, May 04, 2026 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q4 2025 Earnings Call | Fri, Feb 20, 2026 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 7:30 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q2 2025 Earnings Call | Thu, Aug 21, 2025 · 7:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q1 2025 Earnings Call | Tue, May 06, 2025 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q4 2024 Earnings Call | Wed, Feb 19, 2025 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q2 2024 Earnings Call | Fri, Aug 23, 2024 · 5:00 AM ET | Replay |
| ALK-abello (Copenhagen:ALK B) Q1 2024 Earnings Call | Fri, May 03, 2024 · 5:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 17, 2026 · Before open | −2.8% |
| Q2 2026 | Aug 20, 2026 · Before open | −6.5% |
| Q1 2026 | May 4, 2026 · Before open | +7.0% |
| Q4 2025 | Feb 20, 2026 · Before open | −2.5% |
| Q3 2025 | Nov 12, 2025 · After close | +11.5% |
| Q2 2025 | Aug 21, 2025 | +11.2% |
| Q1 2025 | May 6, 2025 · Before open | +4.7% |
| Q4 2024 | Feb 19, 2025 · After close | −5.2% |
| Q3 2024 | Nov 14, 2024 · Before open | +6.0% |
| Q2 2024 | Aug 22, 2024 · After close | +12.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +13.6% |
| Q4 2023 | Feb 8, 2024 · Before open | +8.1% |
| Q3 2023 | Nov 15, 2023 · Before open | +16.7% |
| Q2 2023 | Aug 24, 2023 · Before open | +7.0% |
| Q1 2023 | May 9, 2023 · Before open | +2.0% |
| Q4 2022 | Feb 3, 2023 · Before open | +9.5% |
| Q3 2022 | Nov 10, 2022 · Before open | −9.1% |
| Q2 2022 | Aug 11, 2022 · Before open | +7.8% |
| Q1 2022 | May 12, 2022 · Before open | −3.1% |
| Q4 2021 | Feb 8, 2022 · Before open | −3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 10 slides | Aug 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 11 slides | May 4, 2026 |
| Alk-Abello As B Shs New — FY2025 Earnings Presentation | Earnings | 17 slides | May 4, 2026 |
| Alk-Abello As B Shs New — Q4 2025 Earnings Presentation | Earnings | 12 slides | Feb 20, 2026 |
| Alk-Abello As B Shs New — Q3 2025 Earnings Presentation | Earnings | 10 slides | Nov 13, 2025 |
| Alk-Abello As B Shs New — Q2 2025 Earnings Presentation | Earnings | 12 slides | Aug 21, 2025 |
| Alk-Abello As B Shs New — Q1 2025 Earnings Presentation | Earnings | 12 slides | May 6, 2025 |
| Alk-Abello As B Shs New — Q4 2024 Earnings Presentation | Earnings | 12 slides | Feb 19, 2025 |
| Alk-Abello As B Shs New — Q3 2024 Earnings Presentation | Earnings | 11 slides | Nov 14, 2024 |
| Alk-Abello As B Shs New — Q2 2024 Earnings Presentation | Earnings | 12 slides | Aug 23, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Alk-Abello As B Shs New — Q1 2024 Earnings Presentation | Earnings | 12 slides | May 3, 2024 |
| FY2022 Earnings Presentation | Earnings | 14 slides | Feb 3, 2023 |
| Symposium on Specific Allergy (eSOSA) 2021 | Conference | 13 slides | June 2021 |
| Non-Deal Roadshow (February 2019) | Roadshow | 25 slides | February 2019 |
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.31B | 5.54B | 4.82B | 4.51B | 3.92B | 3.49B | 3.27B | 2.92B | 2.91B | 3.00B |
| Cost of revenue | 2.08B | 1.99B | 1.79B | 1.72B | 1.52B | 1.46B | 1.38B | 1.28B | 1.27B | 1.01B |
| Gross profit | 4.23B | 3.55B | 3.04B | 2.79B | 2.40B | 2.03B | 1.89B | 1.63B | 1.64B | 2.00B |
| Research and development | 609.0M | 531.0M | 618.0M | 665.0M | 631.0M | 515.0M | 466.0M | 392.0M | 426.0M | 385.0M |
| Selling, general and administrative | 1.90B | 369.0M | 331.0M | 276.0M | 240.0M | 237.0M | 246.0M | 227.0M | 231.0M | 230.0M |
| Operating income | 1.65B | 1.09B | 666.0M | 470.0M | 292.0M | 150.0M | -14.0M | -96.0M | -80.0M | 479.0M |
| Depreciation and amortization | 328.0M | 272.0M | 245.0M | 238.0M | 242.0M | 245.0M | 255.0M | 232.0M | 333.0M | 163.0M |
| EBITDA | 1.98B | 1.36B | 911.0M | 708.0M | 534.0M | 395.0M | 241.0M | 136.0M | 253.0M | 642.0M |
| Interest expense | 47.0M | 95.0M | 22.0M | 24.0M | 23.0M | 34.0M | 39.0M | 25.0M | 16.0M | 14.0M |
| Income before tax | 1.64B | 1.06B | 647.0M | 447.0M | 279.0M | 101.0M | -31.0M | -103.0M | -122.0M | 487.0M |
| Income tax | 438.0M | 242.0M | 161.0M | 112.0M | 60.0M | 76.0M | 19.0M | 67.0M | 36.0M | 217.0M |
| Net income | 1.20B | 815.0M | 486.0M | 335.0M | 219.0M | 25.0M | -50.0M | -170.0M | -158.0M | 270.0M |
| Earnings per share, basic | 540.00 | 3.68 | 2.20 | 1.51 | 0.99 | 0.11 | -0.23 | -0.78 | -0.79 | 1.36 |
| Earnings per share, diluted | 540.00 | 3.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.24B | 589.0M | 474.0M | 221.0M | 194.0M | 298.0M | 316.0M | 296.0M | 162.0M | 292.0M |
| Short-term investments | -160.0M | 100.0M | 549.0M | 548.0M | ||||||
| Receivables | 1.09B | 812.0M | 890.0M | 864.0M | 677.0M | 660.0M | 656.0M | 469.0M | 424.0M | 383.0M |
| Inventory | 1.78B | 1.72B | 1.42B | 1.30B | 1.20B | 1.09B | 1.06B | 993.0M | 875.0M | 676.0M |
| Current assets | 4.49B | 3.29B | 2.97B | 2.65B | 2.40B | 2.34B | 2.25B | 2.00B | 2.15B | 1.95B |
| Property, plant and equipment | 2.26B | 2.35B | 2.02B | 1.81B | 1.70B | 1.74B | 1.58B | 1.58B | 1.63B | |
| Goodwill | 455.0M | 463.0M | 459.0M | 460.0M | 457.0M | 452.0M | 461.0M | 465.0M | 461.0M | 422.0M |
| Total assets | 9.06B | 8.25B | 6.73B | 6.31B | 5.83B | 5.56B | 5.50B | 4.87B | 4.96B | 4.80B |
| Accounts payable | 140.0M | 165.0M | 128.0M | 131.0M | 115.0M | 74.0M | 81.0M | 135.0M | 121.0M | 132.0M |
| Current liabilities | 1.33B | 1.95B | 1.31B | 1.40B | 1.39B | 1.03B | 934.0M | 726.0M | 666.0M | 807.0M |
| Long-term debt | 151.0M | 166.0M | 184.0M | 203.0M | 222.0M | 686.0M | 707.0M | 725.0M | 741.0M | 758.0M |
| Total debt | 418.0M | 1.19B | 765.0M | 696.0M | 710.0M | 943.0M | 990.0M | 742.0M | 758.0M | 775.0M |
| Total liabilities | 2.61B | 2.87B | 2.28B | 2.32B | 2.35B | 2.41B | 2.32B | 1.69B | 1.67B | 1.92B |
| Shareholders' equity | 6.45B | 5.37B | 4.45B | 3.99B | 3.48B | 3.15B | 3.18B | 3.18B | 3.29B | 2.88B |
| Shares outstanding | 221.8M | 221.5M | 221.3M | 221.4M | 221.0M | 219.9M | 218.0M | 218.2M | 199.3M | 198.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.82B | 1.21B | 667.0M | 416.0M | 468.0M | 301.0M | 132.0M | -95.0M | -387.0M | 405.0M |
| Capital spending | -276.0M | -260.0M | -379.0M | -298.0M | -263.0M | -222.0M | -167.0M | -178.0M | -267.0M | -225.0M |
| Free cash flow | 1.54B | 953.0M | 288.0M | 118.0M | 205.0M | 79.0M | -35.0M | -273.0M | -654.0M | 180.0M |
| Cash from investing | -385.0M | -1.42B | -375.0M | -351.0M | -266.0M | -245.0M | -157.0M | -199.0M | -358.0M | -204.0M |
| Cash from financing | -760.0M | 310.0M | -31.0M | -42.0M | -311.0M | -62.0M | -57.0M | -28.0M | 620.0M | 39.0M |
| Dividends paid | -51.0M | -49.0M | ||||||||
| Share buybacks | -26.0M | -38.0M | -24.0M | -24.0M | -18.0M | 702.0M | 47.0M | |||
| Change in cash | 672.0M | 106.0M | 253.0M | 27.0M | -104.0M | -18.0M | -80.0M | -315.0M | -129.0M | 232.0M |
Cap table
Built by 6ix from ALK-abello A/S Class B’s releases
- Common shares
- 201,327,842
- Fully diluted
- 201,327,842
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 201,327,842 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 201,327,842 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Jordan Other companies: DBV Technologies SA (EVP and head of Commercial Operations North America · Since at least Dec 1, 2025); Teva Pharmaceutical Industries Limited (EVP and head of Commercial Operations North America · Since at least Dec 1, 2025) | Executive Vice President, Commercial Operations North America · Since at least Dec 1, 2025 |
| Alan Main | Board member · Since at least Nov 5, 2026 |
| Anders Hedegaard | Chair of the Board · Since at least Nov 5, 2026 |
| Bertil Lindmark | Board member · Since at least Nov 5, 2026 |
| Christian G. Houghton | Executive Vice President, Product Supply · Since at least Nov 5, 2026 |
| Claus Steensen Sølje | Executive Vice President & CFO · Since at least Apr 28, 2026 |
| Flora Beiche-Scholz | Executive Vice President, Commercial Operations Europe · Since at least Sep 4, 2025 |
| Gitte Aabo | Board member · Since at least Nov 5, 2026 |
| Jacob Glenting | EVP Global Research & Development · Since at least Nov 5, 2026 |
| Jan Engel | Senior Vice President, Global Quality · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Jesper Høiland | Independent Director · Since at least Nov 4, 2026 |
| Johan Smedsrud | Board member · Since at least Nov 5, 2026 |
| Katja Barnkob | Board Member · Since at least Nov 5, 2026 |
| Lars Holmqvist | Board member · Since at least Nov 5, 2026 |
| Lene Skole | Vice Chair · Since at least Nov 5, 2026 |
| Lika Thiesen | Executive Vice President, Global People & Organisation · Since at least Nov 5, 2026 |
| Lise Lund Mærkedahl | Board member · Since at least Nov 5, 2026 |
| Nanna Carlson | Board Member · Since at least Nov 5, 2026 |
| Peter Halling | President & CEO · Since at least Apr 28, 2026 |
| Tina Abild Olesen | EVP Corporate, Portfolio and Product Strategy · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about ALK-abello A/S.